Thiel-backed Com­pass adds $49M to A round, bring­ing to­tal to $132M

A Cam­bridge start­up that’s been try­ing — and fail­ing — to op­er­ate un­der the radar these past three years is now ready to step in­to the lime­light. Com­pass Ther­a­peu­tics says it’s fi­nal­ly wrapped its years-long quest to raise a Se­ries A mega-round to­tal­ing $132 mil­lion, and it’s head­ing to the clin­ic with a lead im­muno-on­col­o­gy drug.

The com­pa­ny has been col­lect­ing chunks of mon­ey for this raise over the past three years, with word leak­ing rather ear­ly in the fundrais­ing process. Re­porters have dug up fundrais­ing up­dates sev­er­al times since (in­clud­ing a piece not­ing Pe­ter Thiel was a backer), shed­ding some light on the com­pa­ny be­fore it was quite ready, Com­pass CEO Tom Schuetz tells me.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER